Artivion (AORT) vs iRadimed (IRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
iRadimed (IRMD) has outperformed Artivion (AORT) over the past year, losing 9.5% versus a loss of 59.8%. Over five years, IRMD leads with a +91.6% price change compared with -0.8% for AORT. iRadimed is the larger company by market cap ($1.04 billion vs $886.0 million), about 1.2 times the size.
On valuation, iRadimed trades at a lower forward P/E (33.3x vs 34.9x for Artivion). iRadimed pays a dividend yielding 0.99%, while Artivion does not currently pay one. iRadimed converts more of its revenue into profit, with a net margin of 26.8% versus 2.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AORT | IRMD |
|---|---|---|
| Share price | $18.16 | $81.02 |
| Market cap | $886.02M | $1.04B |
| 1-day change | -2.00% | -0.30% |
| YTD return | -60.18% | -16.71% |
| 1-year return | -59.76% | -9.50% |
| 5-year return | -0.82% | +91.58% |
| P/E ratio (TTM) | — | 43.33 |
| Forward P/E | 34.92 | 33.25 |
| EPS (TTM) | $-0.36 | $1.87 |
| Dividend yield | 0.00% | 0.99% |
| Annual dividend | $0.00 | $0.80 |
| Revenue (latest FY) | $441.33M | $83.81M |
| Revenue growth (YoY) | +13.59% | +14.43% |
| Net income (latest FY) | $9.77M | $22.48M |
| Gross margin | 64.40% | 76.75% |
| Operating margin | 7.65% | 31.20% |
| Net margin | 2.21% | 26.82% |
| 52-week high | $48.25 | $107.90 |
| 52-week low | $18.12 | $76.35 |
| Distance from 52-week high | -62.36% | -24.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +111.84% | +45.64% |
| Average volume | 671.97K | 120.89K |
| Shares outstanding | 48.79M | 12.79M |
| Employees | 1,800 | 166 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRMD has outperformed AORT by 50.3 percentage points over the past year.
- iRadimed is more profitable, keeping 26.8 cents of every revenue dollar as net income versus 2.2 cents for Artivion.
About Artivion
AORT stock →Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Health Care · Medical/Dental Instruments · 1,800 employees
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Health Care · Medical/Dental Instruments · 166 employees
AORT vs IRMD FAQ
Which is bigger, Artivion or iRadimed?
iRadimed (IRMD) is larger, with a market capitalization of $1.04B compared with $886.02M for Artivion (AORT).
Which stock has performed better over the past year, AORT or IRMD?
IRMD returned -9.50% over the past 12 months, compared with -59.76% for AORT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Artivion or iRadimed?
iRadimed pays a dividend yielding 0.99%, while Artivion does not currently pay a regular dividend.
Are Artivion and iRadimed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.